Diagnostic efficacy of serum ST2 in patients with ASC

Ren, Yanan; Hou, Min; Ren, Yong; Zhang, Lei

doi:10.1002/jcla.24511

Cited by 4 publications

(1 citation statement)

References 30 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Blood samples were immediately stored in the High Automation CoreLab of our hospital; plasma and serum were aliquoted in Eppendorf tubes and frozen at −80 °C until sST2 and suPAR analysis. The levels of all biomarkers were also examined in a control group of 120 healthy subjects with homogeneous characteristics regarding sex and age [ 35 , 36 , 37 ].…”

Section: Methodsmentioning

confidence: 99%

Multi-Marker Approach in Patients with Acute Chest Pain in the Emergency Department

Piccioni,

Baroni,

Manca

et al. 2024

JPM

View full text Add to dashboard Cite

Background: Chest pain is a prevalent reason for emergency room referrals and presents diagnostic challenges. The physician must carefully differentiate between cardiac and noncardiac causes, including various vascular and extracardiovascular conditions. However, it is crucial not to overlook serious conditions such as acute coronary syndrome (ACS). Diagnosis of acute myocardial infarction (AMI) and early discharge management become difficult when traditional clinical criteria, ECG, and troponin values are insufficient. Recently, the focus has shifted to a “multi-marker” approach to improve diagnostic accuracy and prognosis in patients with chest pain. Methods: This observational, prospective, single-center study involved, with informed consent, 360 patients presenting to the emergency department with typical chest pain and included a control group of 120 healthy subjects. In addition to routine examinations, including tests for hsTnI (Siemens TNIH kit), according to the 0–1 h algorithm, biochemical markers sST2 (tumorigenicity suppression-2) and suPAR (soluble urokinase plasminogen activator receptor) were also evaluated for each patient. A 12-month follow-up was conducted to monitor outcomes and adverse events. Results: We identified two groups of patients: a positive one (112 patients) with high levels of hsTnI, sST2 > 24.19 ng/mL, and suPAR > 2.9 ng/mL, diagnosed with ACS; and a negative one (136 patients) with low levels of hsTnI, suPAR < 2.9 ng/mL, and sST2 < 24.19 ng/mL. During the 12-month follow-up, no adverse events were observed in the negative group. In the intermediate group, patients with hsTnI between 6 ng/L and the ischemic limit, sST2 > 29.1 ng/mL and suPAR > 2.9 ng/mL, showed the highest probability of adverse events during follow-up, while those with sST2 < 24.19 ng/mL and suPAR < 2.9 ng/mL had a better outcome with no adverse events at 12 months. Conclusion: Our data suggest that sST2 and suPAR, together with hsTnI, may be useful in the prognosis of cardiovascular patients with ACS, providing additional information on endothelial damage. These biomarkers could guide the clinical decision on further diagnostic investigations. In addition, suPAR and sST2 emerge as promising for event prediction in patients with chest pain. Their integration into the standard approach in PS could facilitate more efficient patient management, allowing safe release or timely admission based on individual risk.

show abstract

Section: Methodsmentioning

confidence: 99%

Multi-Marker Approach in Patients with Acute Chest Pain in the Emergency Department

Piccioni,

Baroni,

Manca

et al. 2024

JPM

View full text Add to dashboard Cite

show abstract

Diagnostic efficacy of serum ST2 in patients with ASC

Ren

Hou

Ren

et al. 2022

Clinical Laboratory Analysis

Self Cite

View full text Add to dashboard Cite

Background Soluble suppression of tumorigenicity 2 (ST2) is closely related to the development of cardiovascular disease, but the level of acute coronary syndrome (ACS) and the relationship between ST2 and ACS are unclear. Patients and Methods Patients with the acute coronary syndrome were divided into the unstable angina pectoris (USAP) group (n = 65) and non‐ST‐segment elevation myocardial infarction (NSTEMI) group (n = 58), and the healthy population, without chest pain and with normal coronary CT, was included as a control group (n = 55). Laboratory index levels were collected from each participant. The baseline information was reviewed and analyzed. The binary logistic regression was used to explore the relation of ST2 levels with the occurrence of ACS and NSTEMI, and the diagnostic performance of ST2 for diagnosing ACS or NSTEMI was evaluated using a receiver‐operating characteristic (ROC) curve. Results The level of ST2 was found significantly higher in NSTEMI than in USAP and was higher in USAP than in control (p < 0.01). ST2 levels were positively correlated with ALT, AST, and BNP in the control group, were negatively correlated with HGB and TG in the USAP group, and were positively correlated with WBC, GLU, BNP, and Gensini scores in the NSTEMI group. Multivariate analysis revealed that the occurrence of ACS was associated with ST2, BNP, GLU, TC, BUN, WBC, and PLT, and the occurrence of NSTEMI was associated with AST, WBC, LDL‐C, and ST2. Meanwhile, ST2 levels achieved good performance for ACS and NSTEMI diagnostician. Conclusion ST2 could be used as an auxiliary diagnostic indicator for the occurrence of ACS and NSTEMI.

show abstract

Postmortem biochemical analysis of soluble ST2 in the pericardial fluid of patients with sudden cardiac death caused by ischemic heart disease: a pilot study

Zhao

Zhang

et al. 2023

Forensic Sci Med Pathol

View full text Add to dashboard Cite

Diagnostic efficacy of serum ST2 in patients with ASC

Cited by 4 publications

References 30 publications

Multi-Marker Approach in Patients with Acute Chest Pain in the Emergency Department

Multi-Marker Approach in Patients with Acute Chest Pain in the Emergency Department

Diagnostic efficacy of serum ST2 in patients with ASC

Postmortem biochemical analysis of soluble ST2 in the pericardial fluid of patients with sudden cardiac death caused by ischemic heart disease: a pilot study

Contact Info

Product

Resources

About